Hepatocellular carcinoma arising in adenoma: Similar immunohistochemical and cytogenetic features in adenoma and hepatocellular carcinoma portions of the tumor

Modern Pathology

Volumn 27, Issue 11, 2014, Pages 1499-1509

  Kakar, Sanjay ^a,b   Grenert, James P ^a   Paradis, Valerie ^c   Pote, Nicolas ^c   Jakate, Shriram ^d   Ferrell, Linda D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BEAUJON HOSPITAL   (France)

^d RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; BETA CATENIN; GLUTAMATE AMMONIA LIGASE; GLYPICAN 3; HEAT SHOCK PROTEIN 70; MYC PROTEIN; RETICULIN; SERUM AMYLOID A; CTNNB1 PROTEIN, HUMAN; GLYPICAN; GPC3 PROTEIN, HUMAN; MYC PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CHROMOSOME 1; CHROMOSOME 8; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER ADENOMA; LIVER CELL CARCINOMA; MALE; MIDDLE AGED; ONCOGENE MYC; PRIORITY JOURNAL; STEATOSIS; ADENOMA, LIVER CELL; CANCER GRADING; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CHEMISTRY; GENETICS; LIVER NEOPLASMS; NEOPLASMS, COMPLEX AND MIXED; PATHOLOGY; PREDICTIVE VALUE;

ADENOMA, LIVER CELL; ADULT; AGED; BETA CATENIN; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; GLUTAMATE-AMMONIA LIGASE; GLYPICANS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASMS, COMPLEX AND MIXED; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-MYC; SERUM AMYLOID A PROTEIN;

EID: 84926173550     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.50     Document Type: Article

References (46)

1. Dokmak S, Paradis V, Vilgrain V, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009;137:1698-1705.
2. Farges O, Ferreira N, Dokmak S, et al. Changing trends in malignant transformation of hepatocellular adenoma. Gut 2011;60:85-89.
3. Biuolac-Sage P, Balabaud C, Wanless I. Focal nodular hyperplasia and hepatocellular adenoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). WHO Classification of Tumours of the Digestive System, 4th edn. IARC press: Lyon 2010; Chapter 10: pp 198-204.
4. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006;43:515-524.
5. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepa-tology 2007;46:740-748.
6. Deneve JL, Pawlik TM, Cunningham S, et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol 2009;16: 640-648.
7. Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepa-tocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009; 50:481-489.
8. Stoot JH, Coelen RJ, De Jong MC, et al. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford) 2010;12: 509-522.
9. Kakar S, Chen X, Ho C, et al. Chromosomal abnormalities determined by comparative genomic hybridization are helpful in the diagnosis of atypical hepatocellular neoplasms. Histopathology 2009;55: 197-205.
10. Evason KJ, Grenert JP, Ferrell LD, et al. Atypical hepatocellular adenoma-like neoplasms with b-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol 2013;44:750-758.
11. Ishak KG, Goodman ZD, Stocker JT. Benign hepatocel-lular tumors. In: Tumors of the Liver and Intrahepatic Bile Ducts. AFIP press: Washington DC, 1999; Chapter 2 p21.
12. Ferrell LD, Crawford JM, Dhillon AP, et al. Proposal for standardized criteria for the diagnosis of benign, borderline, and malignant hepatocellular lesions arising in chronic advanced liver disease. Am J Surg Pathol 1993;17:1113-1123.
13. Anonymous, International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22:983-993.
14. Davis M, Portmann B, Searle M, et al. Histological evidence of carcinoma in a hepatic tumour associated with oral contraceptives. Br Med J 1975;4:496-498.
15. Korula J, Yellin A, Kanel G, et al. Hepatocellular carcinoma coexisting with hepatic adenoma. Incidental discovery after long-term oral contraceptive use. West J Med 1991;155:416-418.
16. Ferrell LD. Hepatocellular carcinoma arising in a focus of multilobular adenoma. A case report. Am J Surg Pathol 1993;17:525-529.
17. Chuang WY, Chen TC, Hsu HL, et al. Liver cell adenoma with concomitant hepatocellular carcinoma: report of two cases. J Formos Med Assoc 2002;101: 798-802.
18. Burri E, Steuerwald M, Cathomas G, et al. Hepatocel-lular carcinoma in a liver-cell adenoma within a non-cirrhotic liver. Eur J Gastroenterol Hepatol 2006; 18:437-441.
19. Colovic R, Grubor N, Micev M, et al. Hepatocellular adenoma with malignant alteration. Hepatogastroen-terology 2007;54:386-388.
20. Kim DH, Kim SU, Nam DH, et al. A case of hepatocellular carcinoma within hepatocellular adenoma in a non-cirrhotic male. Korean J Intern Med 2009;24:147-152.
21. Seo JM, Lee SJ, Kim SH, et al. Hepatocellular carcinoma arising from hepatocellular adenoma in a hepatitis B virus-associated cirrhotic liver. Clin Radiol 2012;67:329-333.
22. Gyorffy EJ, Bredfeldt JE, Black WC. Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use. Ann Intern Med 1989;110: 489-490.
23. Tesluk H, Lawrie J. Hepatocellular adenoma. Its transformation to carcinoma in a user of oral contraceptives. Arch Pathol Lab Med 1981;105:296-299.
24. Gordon SC, Reddy KR, Livingstone AS, et al. Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med 1986;105:547-549.
25. Audard V, Grimber G, Elie C, et al. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J Pathol 2007;212:345-352.
26. Dal Bello B, Rosa L, Campanini N, et al. Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation. Clin Cancer Res 2010;16:2157-2166.
27. Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas Oncogene 2002;21:4863-4871.
28. Kim YD, Park CH, Kim HS, et al. Genetic alterations of Wnt signaling pathway-associated genes in hepatocel-lular carcinoma. J Gastroenterol Hepatol 2008;23: 110-118.
29. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005;18:1591-1598.
30. Wang XY, Degos F, Dubois S, et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006;37:1435-1441.
31. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol 2008;21: 1011-1018.
32. Chuma M, Sakamoto M, Yamazaki K, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003;37: 198-207.
33. Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007;45:725-734.
34. Di Tommaso L, Destro A, Seok JY. Balladore et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009;50:746-754.
35. Lagana SM, Salomao M, Bao F, et al. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma. Appl Immunohisto-chem Mol Morphol 2013;21:170-176.
36. Nguyen T, Kakar S. Utility of HSP70, glutamine synthethase and glypican-3 in distinguishing hepatocel-lular adenoma from well-differentiated hepatocellular carcinoma. Mod Pathol 2012;25:420A (abstract 1753).
37. Balsara BR, Pei J, De Rienzo A, et al. Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes Cancer 2001;30:245-253.
38. Poon TC, Wong N, Lai PB, et al. A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology 2006;131: 1262-1270.
39. Wilkens L, Bredt M, Flemming P, et al. Differentiation of liver cell adenomas from well-differentiated hepatocellular carcinomas by comparative genomic hybridization. J Pathol 2001;193:476-482.
40. Wilkens L, Bredt M, Flemming P, et al. Diagnostic impact of fluorescence in situ hybridization in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma. J Mol Diagn 2001;3:68-73.
41. Mao TL, Chu JS, Jeng YM, et al. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol 2001;193:95-101.
42. Fujito T, Sasaki Y, Iwao K, et al. Prognostic significance of beta-catenin nuclear expression in hepatocellular carcinoma. Hepatogastroenterology 2004;51:921-924.
43. Tward AD, Jones KD, Yant S, et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci USA 2007;104:14771-14776.
44. Witjes CD, Ten Kate FJ, van Aalten SM, et al. Hepato-cellular adenoma as a risk factor for hepatocellular carcinoma in a non-cirrhotic liver: a plea against. Gut 2012;61:1645-1646.
45. Bedossa P, Burt AD, Brunt EM, et al. Well differentiated hepatocellular neoplasm of uncertain malignant potential (HUMP): Proposal for a new diagnostic category. Hum Pathol 2014;45:658-660.
46. Kakar S, Evason KJ, Ferrell LD. Well-differentiated hepatocellular neoplasms: getting over the 'HUMP'. Hum Pathol 2014;45:660-661.